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AbstrAct:
The Hedgehog (HH) signaling pathway leads to activation of GLI, which 
transcriptionally regulate target genes. Regulated HH signaling activity is critical 
during embryogenesis while aberrantly activated HH signaling is evident in a variety 
of human cancers. Canonical HH signaling engages the transmembrane receptor 
Patched (PTCH) and the signaling intermediate Smoothened (SMO) to activate GLI1 
and GLI2.  In addition GLI1 and GLI2 are activated by non-canonical oncogenic 
signaling pathways to further drive HH-dependent survival. We have demonstrated 
in human colon carcinoma cells that inhibition of the RAS/RAF pathway by U0126 
decreases p-ERK protein expression and also inhibits GLI-luciferase activity and 
GLI1 mRNA and protein levels. Of importance is the demonstration that targeting 
of SMO (using cyclopamine) has minimal effect on cell survival in comparison 
to the inhibition of GLI (using GANT61), which induced extensive cell death in 
7/7 human colon carcinoma cell lines. Genetic inhibition of the function of GLI1 
and GLI2 by transient transfection of the C-terminus deleted repressor GLI3R, 
reduced proliferation and induced cleavage of caspase-3 and cell death in HT29 
cells, similar to the effects of GANT61.  Mechanistically, downstream of GLI1 and 
GLI2 inhibition, γH2AX (a marker of DNA double strand breaks) expression was 
upregulated,  and  γH2AX  nuclear  foci  were  demonstrated  in  cells  that  expressed 
GLI3R.  Activation of the ATM/Chk2 axis with co-localization of γH2AX and p-Chk2 
nuclear foci were demonstrated following GLI1/GLI2 inhibition. GANT61 induced 
cellular accumulation at G1/S and early S with no further progression before cells 
became subG1, while cDNA microarray gene profiling demonstrated downregulation 
of genes involved in DNA replication, the DNA damage response, and DNA repair, 
mechanisms that are currently being pursued.  These studies highlight the importance 
of targeting the GLI genes downstream of SMO for terminating HH-dependent 
survival, suggesting that GLI may constitute a molecular switch that determines 
the balance between cell survival and cell death in human colon carcinoma.
cANONIcAL HEDGEHOG sIGNALING 
IN cANcEr
Canonical HH signaling engages PTCH, SMO and 
the GLI family of transcription factors (Figure 1), and in 
normal cellular processes is involved in embryogenesis, 
tissue patterning, stem cell function, and differentiation[1, 
2]. Several types of human cancers have demonstrated 
aberrant activation of the HH pathway by ligand-
independent signaling such as, amplification of GLI1 or 
GLI2, mutations in PTCH or SMO, or dysregulated gene 
expression[1, 3]. In colon cancer, aberrant HH signaling 
progresses during carcinogenesis and in metastatic 
disease[4-6], and is also activated in human colon 
carcinoma cell lines[7-9] and xenograft models[4], by 
ligand-dependent activation, that occurs in GI cancers[1, 
10]. However, the role of HH signaling and its importance Oncotarget 2011; 2:  638 - 645 639 www.impactjournals.com/oncotarget
in driving cellular survival in colon cancer are not well 
defined.  Small  molecule  inhibitors  of  SMO  have  been 
studied in preclinical models, and applied to the treatment 
of various types of cancers in humans[4, 9, 11-14]. Those 
tumors sensitive to SMO inhibitors, which include basal 
cell carcinoma[15, 16] and medulloblastoma[11, 17], 
rely on canonical HH signaling for cellular survival. In 
other cancer types, SMO inhibitors including GDC-0449, 
IPI-926 or LDE225, have demonstrated limited clinical 
activity (reviewed in [11, 12]). Intrinsic resistance to 
SMO inhibitors is frequent[11-14, 18, 19], and acquired 
resistance to GDC-0449 following initial response has 
been reported in medulloblastoma (heterozygous mutation, 
Asp->His at aa 473 in SMO)[20]. Thus targeting the GLI 
genes downstream of SMO, that constitute the core of 
HH-dependent gene regulation, may provide a significant 
advantage in eliminating HH signaling. 
ActIvAtION Of GLI by ONcOGENIc, 
NON-cANONIcAL sIGNALING 
pAtHwAys
Non-canonical, oncogene-driven signaling pathways 
converge on the activation of GLI genes and further 
converge on their specific downstream targets[3, 18, 21, 
22] (see Figure 1). The RAS/RAF/MEK/ERK pathway, 
with activating mutations in K-RAS or B-RAF that occur 
in high frequency in colon cancers[23-25], activates GLI 
function[18, 19, 21]. In HT29 cells (mutated B-RAF 
V600E[25]), we demonstrated inhibition of GLI-
luciferase reporter activity, reduced expression of GLI1 
mRNA and protein, and of p-ERK in response to the 
MEK/ERK and RAS/RAF signaling inhibitor U0126[26, 
27] (Figure 2). While loss-of-function mutations in 
PTCH and gain-of-function mutations in SMO activate 
HH signaling[1], acquired mutations in SMO or non-
canonical GLI activation render cancer cells resistant 
to SMO antagonists. These observations emphasize the 
importance of targeting the GLI genes downstream of 
SMO for terminating HH-dependent survival and inducing 
cell death in colon carcinoma cells. It therefore follows 
that termination of HH signaling at the level of GLI may 
constitute a molecular switch that determines the balance 
between cell survival or cell death.
tArGEtING GLI1 AND GLI2 wItH 
GANt61
One of the gaps in our knowledge is that the impact 
of terminating HH signaling at the level of the GLI genes is 
unclear. The GLI family of transcription factors regulates 
target gene expression that determines HH-dependent 
survival. GLI1 and GLI2 are the primary activators of 
HH signaling; further, the cooperative roles of GLI1 and 
GLI2 are critical in the transcriptional regulation of HH 
target genes[1, 28-30]. While SMO has been extensively 
investigated as a therapeutic target[11-15, 17], few agents 
are available that target the GLI genes[31]. GANT61 
figure 1: canonical HH signaling and non-
canonical GLI gene activation.
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figure 2:  Inhibition of the rAs/rAf pathway by UO126 (20 µM) decreases GLI-luc activity (left), GLI1 mrNA 
(center), GLI1 and p-ErK1/2 proteins (right). 
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was identified in a cell-based screen for small molecule 
inhibitors of GLI1-mediated transcription. In the original 
study[31], GANT61 1) functions in the nucleus to abrogate 
GLI function; 2) blocks both GLI1- and GLI2- mediated 
transcription; 3) in SUFU-null MEFS with constitutively 
active HH signaling, reduces expression of GLI1 and 
HIP1 mRNA in contrast to cyclopamine; 4) inhibits 
GLI1 DNA binding activity (EMSA analysis). We further 
demonstrated  the  specificity  of  GANT61  in  targeting 
GLI1 and GLI2 from reduced GLI1 and GLI2 protein 
expression[8], inhibition of the binding of GLI1 and GLI2 
to the promoter regions of HH target genes, specificity of 
reduction in GLI-luciferase reporter activity, and rapid 
inhibition of the transcriptional regulation of the GLI 
target gene BCL-2, within 1 hr of GANT61 exposure[7]. 
INHIbItION Of GLI INDUcEs GrEAtEr 
cytOtOxIcIty tHAN tArGEtING 
sMO
GANT61, and the classic SMO inhibitor 
cyclopamine (for comparison with other model systems), 
were evaluated in a panel of human colon carcinoma 
cell lines to determine the impact of inhibiting GLI1/
GLI2 vs SMO. Inhibition of GLI1 and GLI2 by GANT61 
induced > 80% cell death in 5/7 human colon carcinoma 
cell lines following 72 hr exposure (20 µM). In contrast, 
cyclopamine induced < 30% cell death in 6/7 cell lines, 
at equimolar concentrations (20 µM; Figure 3). In time 
course studies, 24 hr exposure to GANT61 or 72 hr 
exposure to cyclopamine was required to initiate cell 
death[8]. In addition the SMO inhibitor GDC-0449, like 
cyclopamine, demonstrated limited cytotoxic activity 
in HT29 cells at equimolar concentrations (unpublished 
data). Collectively, the data demonstrate increased 
sensitivity of human colon cancer cells to inhibition of GLI 
figure 3: GANt61- and cyclopamine- induced cell 
death.
figure 4:  treatment of Ht29 cells with vehicle alone (0.2% DMsO) or GANt61 (20 µM; upper panel), or transient 
transfection of vector alone, or GLI3r-pcs2-Mt[4, 34](lower panel) for 72 hr. Expression of proteins was by western 
analysis and analyzed by densitometry. 
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genes compared to that of SMO. This is consistent with 
the presence of a non-canonical mode of GLI activation in 
human colon cancer cells. These concentrations and time 
frames for the induction of cellular effects are similar to 
those determined in other model systems for inhibitors of 
HH signaling[4, 19, 33].
GENEtIc DOwNrEGULAtION Of 
GLI1 AND GLI2 by GLI3r pArALLELs 
cELLULAr EffEcts MEDIAtED by 
pHArMAcOLOGIc INHIbItION Of 
GLI1 AND GLI2 by GANt61
A third member of the GLI family is GLI3. A 
cleaved C-terminally truncated form of GLI3 (GLI3R) 
demonstrates repressor activity for GLI1 and GLI2 
transcriptional regulation, and thereby silences HH-GLI 
target genes[4, 34]. We confirmed the critical role of GLI1 
and GLI2 in cell survival by genetic downregulation 
of GLI1 and GLI2 following transient transfection of 
GLI3R[4, 34] in HT29 cells. Transient transfection and 
expression of GLI3R (GLI3R-pCS2-MT, N-terminal 
Myc-epitope tag) over a period of 72 hr paralleled the 
effects of GANT61 by inducing significant changes in 
cellular morphology, reduced expression of GLI1 and 
GLI2, reduced proliferation, and induction of cell death. 
GLI3R-myc expression was detected by 24 hr, with 
strong expression by 48 hr[32]. Under these conditions of 
GLI3R transient transfection, GLI1 and GLI2 expression 
was  decreased,  with  significant  cleavage  of  caspase-3 
(Figure 4). To begin to explore the cellular mechanisms 
downstream of GLI1/GLI2 inhibition that lead to cell 
death, we demonstrated that γH2AX, a marker of DNA 
DSBs[35], was expressed in GANT61-treated cells 
(Figure 4). Further, γH2AX nuclear foci were detected in 
the cells expressing GLI3R-myc[32]. Thus, both genetic 
and pharmacologic downregulation of GLI1 and GLI2 
induce parallel changes in events leading to cell death, 
including the induction of γH2AX nuclear foci. One of the 
critical regulators of DNA damage response is p53, which 
is stabilized upon DNA damage and modulates multiple 
components of the DNA damage response pathway[36, 
37]. Expression of Gli3R-myc in human colon carcinoma 
cell lines harboring mutant p53 (functionally inactive) 
demonstrated DNA damage response suggesting a p53 
independent mechanism[32]. Further, GANT61 treatment 
of HT29 cells demonstrated a p21Cip1-independent 
mechanism of cell death[32]. 
INHIbItION Of GLI1/GLI2 by GANt61 
INDUcEs DNA DAMAGE vIA AtM/cHK2 
sIGNALING 
To further investigate the molecular mechanisms 
underlying DNA damage signaling downstream of GLI1/
GLI2 inhibition, HT29 cells treated with GANT61 (20 
µM) were examined for expression of the phosphorylated 
(active) forms of ATM, ATR, Chk1 and Chk2 by Western 
analysis or by confocal microscopy. p-ATM and p-Chk2 
were detected as early as 4 hr, and their expression was 
sustained for at least 24 hr. In contrast, p-ATR and p-Chk1 
Figure  5:    Co-localization  of  γH2AX  and  p-Chk2 
nuclear foci following GANt61 (20 µM) for 4 hr in 
Ht29 cells.
figure 6. A: Flow cytometric analysis of propidium iodide-stained HT29 cells at 0 hr, or after GANT61 (20 µM) for 32 hr[7], or FUra 
(1.5 µM/leucovorin 1 µM) for 24 hr. b: Expression profile of proteins involved in activation of the intra-S-phase checkpoint (western).
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expression remained undetectable[32]. p-Chk2 nuclear 
foci co-localized with γH2AX nuclear foci at the sites 
of DNA DSBs in GANT61-treated cells (Figure 5). An 
ATM/Chk2 axis was therefore activated in GANT61-
treated human colon carcinoma cells as an early event in 
the response to DNA damage. 
INHIbItION Of GLI1/GLI2 by GANt61 
INDUcEs ArrEst IN EArLy s 
Using HT29 cells we have demonstrated that cells 
treated with GANT61 (20 µM) accumulate in early 
S-phase and fail to progress further through or beyond 
early S before becoming subG1[7, 32]. By cell cycle 
analysis, cells were observed to move from G1 into early 
S by 32 hr where they remain, detected as two discrete 
peaks (G1/S, early S; Figure 6A). Analysis by FACS/
BrdU incorporation at 32 hr after GANT61 exposure 
demonstrated a shift in G1/S-phase cells from 8.0% BrdU 
incorporation in the control to 52.3% at 32 hr, and S-phase 
cells from 25.0% to 33.6%[32]. In contrast 5-fluorouracil 
(FUra) combined with leucovorin (1 µM), which targets 
thymidylate synthase in the inhibition of DNA replication 
and induction of DNA damage, arrested HT29 cells in mid 
S-phase[38] (67.0% by FACS/PI staining; Figure 6A), 
thereby demonstrating the difference in S-phase target 
location of the mechanism of GANT61-induced inhibition 
of DNA replication. The cell cycle checkpoints constitute 
a regulatory mechanism to arrest the cell cycle in response 
to DNA damage so that cell cycle progression and repair 
may be temporally coordinated[39-42]. In contrast to 
the checkpoints at the G1/S and G2/M transitions, the 
S-phase checkpoint can only delay the progression of 
S-phase. ATM is the master transducer of the S-phase 
checkpoint, responds to DNA DSBs, and together with 
its effector kinase Chk2, is activated in response to GLI1/
GLI2 inhibition by GANT61. In activation of the intra-S-
phase checkpoint, Cdc25A is phosphorylated on Ser123, 
which targets this phosphatase for degradation by the 
proteasome. Activation of Cdk2 and the loading of Cdc45 
onto replication origins are inhibited, DNA replication 
is inhibited, the intra-S-phase checkpoint is activated, 
and cyclin E accumulates[43-45], as demonstrated 
in GANT61-treated HT29 cells at 24 hr (Figure 6B). 
Accumulation of HT29 cells in early S[9](Figure 6A), and 
the data of Figure 6B, suggest activation of an intra-S-
phase checkpoint, which is not sustained. 
GANt61 MODULAtEs GENEs 
DOwNstrEAM Of GLI1/GLI2 
INHIbItION INvOLvED IN tHE DNA 
DAMAGE rEspONsE
To identify unique downstream targets of the GLI 
genes, analysis with cDNA microarray gene profiling of 
18,401 genes identified Differentially Expressed Genes 
(DEGs) in HT29 (and GC3/c1)[7]. Analyses using 
GenomeStudio (statistics), Matlab (heat map), Ingenuity 
(canonical pathway analysis), or by qRT-PCR, identified 
decreased expression of mRNA for genes involved 
in DNA replication (including thymidylate synthase, 
thymidine kinase, topoisomerase2, DNA polymerases, 
E2F, replication factor C); DNA damage (including 
H2AX, MDC1, BRCA1, FANCD2, GADD45G, 
GADD153, REDD1, PCNA); and DNA repair (including 
RAD51, RAD54, FEN1, MSH6, Exonuclease 1), 24 hr 
after GANT61 exposure (20 µM; Table 1).
Table 1: Decreased expression of genes downstream of GLI1/GLI2 inhibition following GANT61 (20 μM), 
24 hr, HT29 cells; cDNA microarray gene profiling.
Function Fold change Genes
DNA replication -2.0 to -4.2 TYMS, TK1, TOP2A, RRM1, RRM2, PRPS2, 
POLE, POLE2, POLA1, POLA2, POLQ, 
E2F2, CDT1, PRIM1, GMNN, RFC2, RFC3, 
RFC4, RFC5
DNA damage response -1.9 to -4.9 H2AFX, MDC1, BRCA1, FANCD2, BARD1, 
CDC45L, DDIT2, DDIT3, DDIT4, 
PPP1R15A, PCNA, ATF3
DNA repair -1.9 to -4.2 RAD51, RAD51C, RAD54B, RAD54L, 
FEN1, MSH6, KIAA0101, UNG, LIG1, 
EXO1, HELLSOncotarget 2011; 2:  638 - 645 643 www.impactjournals.com/oncotarget
sUMMAry AND fUtUrE DIrEctIONs
We have demonstrated in human colon carcinoma 
cells that the GLI genes, the transcriptional regulators of 
the HH signaling response, are activated by both canonical 
signaling (via SMO) and by non-canonical activation 
(via the RAS/RAF pathway), which is activated in high 
frequency in colon cancers. Both pharmacologic and 
genetic inhibition of GLI function reduced proliferation, 
GLI1 and GLI2 expression, induced γH2AX expression, 
cleavage of caspase-3, and cell death. In contrast 
inhibition  of  SMO  was  significantly  less  effective  at 
inducing cell death in contrast to targeting GLI. DNA 
damage signaling involved an ATM/Chk2 axis, with Chk2 
co-localizing with γH2AX at the sites of DNA DSBs. 
Further, cells accumulated in early S-phase following 
GANT61 exposure but did not progress before becoming 
subG1, suggesting an intra-S-phase checkpoint that could 
not be sustained. From cDNA microarray gene profiling, 
genes involved in the inhibition of DNA replication, 
DNA damage response, and DNA repair were identified 
downstream of GANT61-induced GLI1/GLI2 inhibition. 
Chromosome instability is found in the majority of colon 
cancers, resulting primarily from deregulation of the DNA 
replication and mitotic spindle checkpoints (reviewed in 
[45]). Genes involved in canonical HH signaling have been 
linked to genomic instability, involving inactivation of 
DNA repair mechanisms, defects in checkpoint activation, 
and predisposition to development of cancers[46-49]. It 
therefore follows that termination of HH signaling at the 
level of GLI may constitute a critical event in determining 
the balance between cell survival and cell death. The 
combination of molecular and cellular approaches that are 
being employed will 1) provide critical new insight into 
the role of GLI1/GLI2 in driving cellular survival, which 
has never been addressed in any type of human cancer, 
and will answer a fundamental question in HH biology, 2) 
address how dysregulation of the GLI1/GLI2 axis induces 
DNA damage upstream of cell death or DNA repair 
upstream of cell survival and 3) provide a framework 
for the design of strategies and therapeutics specifically 
targeted at HH signaling via GLI1 and GLI2 in human 
colon carcinoma. 
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